| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
|
N Engl J Med
|
2006
|
5.70
|
|
2
|
Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review.
|
JAMA
|
2006
|
4.87
|
|
3
|
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
|
Cancer Discov
|
2011
|
4.78
|
|
4
|
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
|
J Clin Oncol
|
2012
|
4.77
|
|
5
|
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.
|
Nat Med
|
2004
|
4.69
|
|
6
|
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
|
Cancer Prev Res (Phila)
|
2011
|
3.33
|
|
7
|
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
|
Cancer Prev Res (Phila)
|
2011
|
3.03
|
|
8
|
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
|
Clin Cancer Res
|
2005
|
2.98
|
|
9
|
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.
|
Proc Natl Acad Sci U S A
|
2005
|
2.96
|
|
10
|
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
|
Cancer Res
|
2005
|
2.48
|
|
11
|
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
|
PLoS Genet
|
2013
|
2.39
|
|
12
|
Potential markers that complement expression of CA125 in epithelial ovarian cancer.
|
Gynecol Oncol
|
2005
|
2.34
|
|
13
|
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
|
Clin Cancer Res
|
2005
|
2.29
|
|
14
|
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.
|
Genome Res
|
2012
|
2.27
|
|
15
|
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.
|
Clin Cancer Res
|
2006
|
2.24
|
|
16
|
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
|
Gynecol Oncol
|
2007
|
2.20
|
|
17
|
Expanding the criteria for BRCA mutation testing in breast cancer survivors.
|
J Clin Oncol
|
2010
|
2.12
|
|
18
|
Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?
|
Obstet Gynecol
|
2004
|
2.09
|
|
19
|
Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study.
|
J Clin Oncol
|
2014
|
2.05
|
|
20
|
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
|
J Clin Oncol
|
2010
|
1.95
|
|
21
|
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
|
Obstet Gynecol
|
2006
|
1.93
|
|
22
|
Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.
|
Obstet Gynecol
|
2010
|
1.89
|
|
23
|
Testing women with endometrial cancer to detect Lynch syndrome.
|
J Clin Oncol
|
2011
|
1.72
|
|
24
|
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.
|
Gynecol Oncol
|
2003
|
1.72
|
|
25
|
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
|
Cancer
|
2008
|
1.69
|
|
26
|
Endometrial cancer and Lynch syndrome: clinical and pathologic considerations.
|
Cancer Control
|
2009
|
1.66
|
|
27
|
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
|
Cancer
|
2010
|
1.61
|
|
28
|
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
|
Gynecol Oncol
|
2009
|
1.61
|
|
29
|
Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases.
|
Gynecol Oncol
|
2004
|
1.58
|
|
30
|
Association between adiponectin, insulin resistance, and endometrial cancer.
|
Cancer
|
2006
|
1.55
|
|
31
|
Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome.
|
J Clin Oncol
|
2008
|
1.49
|
|
32
|
Are women ready for the HPV vaccine?
|
Gynecol Oncol
|
2006
|
1.47
|
|
33
|
Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma.
|
Cancer
|
2006
|
1.47
|
|
34
|
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
|
Am J Pathol
|
2010
|
1.46
|
|
35
|
Understanding obesity and endometrial cancer risk: opportunities for prevention.
|
Am J Obstet Gynecol
|
2011
|
1.42
|
|
36
|
Cyclin E deregulation alters the biologic properties of ovarian cancer cells.
|
Oncogene
|
2004
|
1.41
|
|
37
|
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
|
Nat Commun
|
2013
|
1.36
|
|
38
|
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.
|
Cancer
|
2011
|
1.33
|
|
39
|
Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy.
|
Gynecol Oncol
|
2002
|
1.31
|
|
40
|
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
|
J Clin Oncol
|
2004
|
1.28
|
|
41
|
Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative.
|
J Clin Oncol
|
2014
|
1.27
|
|
42
|
Risk factors for young premenopausal women with endometrial cancer.
|
Obstet Gynecol
|
2005
|
1.26
|
|
43
|
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary.
|
Cancer Biol Ther
|
2006
|
1.26
|
|
44
|
What women with ovarian cancer think and know about genetic testing.
|
Gynecol Oncol
|
2008
|
1.26
|
|
45
|
Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.
|
Cancer Res
|
2006
|
1.24
|
|
46
|
Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
|
Gynecol Oncol
|
2007
|
1.24
|
|
47
|
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.
|
Am J Obstet Gynecol
|
2011
|
1.24
|
|
48
|
Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
|
Clin Cancer Res
|
2004
|
1.22
|
|
49
|
Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.
|
Am J Obstet Gynecol
|
2011
|
1.12
|
|
50
|
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
|
Cancer
|
2003
|
1.12
|
|
51
|
Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.
|
Clin Cancer Res
|
2003
|
1.09
|
|
52
|
Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model.
|
Am J Obstet Gynecol
|
2007
|
1.09
|
|
53
|
PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.
|
Mod Pathol
|
2009
|
1.08
|
|
54
|
Limited public knowledge of obesity and endometrial cancer risk: what women know.
|
Obstet Gynecol
|
2008
|
1.07
|
|
55
|
Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome?
|
J Clin Oncol
|
2005
|
1.06
|
|
56
|
Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
|
Int J Gynecol Pathol
|
2007
|
1.06
|
|
57
|
Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
|
J Clin Oncol
|
2009
|
1.05
|
|
58
|
Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
|
Cancer
|
2011
|
1.04
|
|
59
|
Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
|
Mol Cancer Ther
|
2013
|
1.04
|
|
60
|
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
|
J Cancer Res Clin Oncol
|
2011
|
1.04
|
|
61
|
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.
|
Gynecol Oncol
|
2011
|
1.04
|
|
62
|
Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome.
|
Cancer
|
2008
|
1.04
|
|
63
|
Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases.
|
Am J Surg Pathol
|
2002
|
1.03
|
|
64
|
BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
|
J Clin Oncol
|
2007
|
1.03
|
|
65
|
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
|
Gynecol Oncol
|
2007
|
1.03
|
|
66
|
Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2004
|
1.02
|
|
67
|
Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression.
|
Cancer Biol Ther
|
2009
|
1.02
|
|
68
|
Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study.
|
Am J Obstet Gynecol
|
2010
|
1.01
|
|
69
|
beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma.
|
Gynecol Oncol
|
2003
|
1.00
|
|
70
|
The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.
|
Am J Surg Pathol
|
2011
|
0.98
|
|
71
|
Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome.
|
Mod Pathol
|
2004
|
0.95
|
|
72
|
Endometrial cancer in an adolescent: a possible manifestation of Cowden syndrome.
|
Obstet Gynecol
|
2009
|
0.94
|
|
73
|
Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes.
|
Fam Cancer
|
2010
|
0.94
|
|
74
|
Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry.
|
Fam Cancer
|
2012
|
0.93
|
|
75
|
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation.
|
Cancer
|
2009
|
0.93
|
|
76
|
Obstetrics/gynecology residents' knowledge of hereditary breast and ovarian cancer and Lynch syndrome.
|
J Cancer Educ
|
2010
|
0.93
|
|
77
|
Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome.
|
Obstet Gynecol
|
2010
|
0.93
|
|
78
|
Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.
|
Cancer Prev Res (Phila)
|
2011
|
0.93
|
|
79
|
Chemopreventive effects of metformin on obesity-associated endometrial proliferation.
|
Am J Obstet Gynecol
|
2013
|
0.93
|
|
80
|
Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.92
|
|
81
|
Enhanced estrogen-induced proliferation in obese rat endometrium.
|
Am J Obstet Gynecol
|
2009
|
0.92
|
|
82
|
Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
|
Obstet Gynecol
|
2006
|
0.92
|
|
83
|
Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis.
|
Int J Mol Epidemiol Genet
|
2010
|
0.91
|
|
84
|
Endometrial cancer in young, normal-weight women.
|
Gynecol Oncol
|
2005
|
0.90
|
|
85
|
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
|
J Natl Cancer Inst
|
2015
|
0.90
|
|
86
|
STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study.
|
Gynecol Oncol
|
2007
|
0.89
|
|
87
|
Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care.
|
Cancer Prev Res (Phila)
|
2012
|
0.88
|
|
88
|
Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
|
Gynecol Oncol
|
2007
|
0.88
|
|
89
|
Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer.
|
Clin Cancer Res
|
2005
|
0.87
|
|
90
|
Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer.
|
J Exp Clin Cancer Res
|
2011
|
0.87
|
|
91
|
Practice patterns of SGO members for stage IIIA endometrial cancer.
|
Gynecol Oncol
|
2005
|
0.87
|
|
92
|
Accuracy of the BRCAPRO model among women with bilateral breast cancer.
|
Cancer
|
2009
|
0.86
|
|
93
|
Prospective evaluation of insulin resistance among endometrial cancer patients.
|
Am J Obstet Gynecol
|
2011
|
0.86
|
|
94
|
Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women.
|
Obstet Gynecol
|
2008
|
0.85
|
|
95
|
Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
|
Gynecol Oncol
|
2011
|
0.85
|
|
96
|
MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
|
Cancer
|
2009
|
0.85
|
|
97
|
Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer.
|
Genet Med
|
2009
|
0.84
|
|
98
|
Genetic polymorphisms and endometrial cancer risk.
|
Expert Rev Anticancer Ther
|
2008
|
0.84
|
|
99
|
Genotype in BRCA-associated breast cancers.
|
Breast J
|
2012
|
0.84
|
|
100
|
Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
|
Cancer Res
|
2003
|
0.83
|
|
101
|
Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer.
|
Int J Gynecol Cancer
|
2016
|
0.83
|
|
102
|
Sex hormone regulation of survivin gene expression.
|
J Endocrinol
|
2010
|
0.82
|
|
103
|
Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes.
|
Fam Cancer
|
2014
|
0.82
|
|
104
|
Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas.
|
Appl Immunohistochem Mol Morphol
|
2005
|
0.82
|
|
105
|
FATS is a transcriptional target of p53 and associated with antitumor activity.
|
Mol Cancer
|
2010
|
0.82
|
|
106
|
Overexpression of kallikrein 10 in epithelial ovarian carcinomas.
|
Gynecol Oncol
|
2003
|
0.81
|
|
107
|
Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome.
|
BMC Cancer
|
2008
|
0.81
|
|
108
|
The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
|
Int J Gynecol Cancer
|
2014
|
0.81
|
|
109
|
Supracervical hysterectomy in patients with advanced epithelial ovarian cancer.
|
Obstet Gynecol
|
2007
|
0.81
|
|
110
|
Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
|
Gynecol Oncol
|
2004
|
0.81
|
|
111
|
Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer.
|
Curr Pharm Des
|
2014
|
0.80
|
|
112
|
Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation.
|
Haematologica
|
2005
|
0.79
|
|
113
|
Management for Elderly Women With Advanced-Stage, High-Grade Endometrial Cancer.
|
Obstet Gynecol
|
2015
|
0.79
|
|
114
|
Commenting on "HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? (88:263-5) by Santin AD".
|
Gynecol Oncol
|
2004
|
0.78
|
|
115
|
Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist.
|
Gynecol Oncol
|
2013
|
0.78
|
|
116
|
Does a BRCA mutation plus tamoxifen equal hysterectomy?
|
Gynecol Oncol
|
2007
|
0.78
|
|
117
|
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.
|
Cancer
|
2010
|
0.78
|
|
118
|
Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.
|
Cancer
|
2014
|
0.78
|
|
119
|
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era.
|
Int J Gynecol Cancer
|
2013
|
0.77
|
|
120
|
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.
|
Gynecol Oncol
|
2013
|
0.77
|
|
121
|
Women with HNPCC: a target population for the chemoprevention of gynecologic cancers.
|
Front Biosci
|
2006
|
0.77
|
|
122
|
Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
|
Gynecol Oncol
|
2010
|
0.76
|
|
123
|
Genetic risk and gynecologic cancers.
|
Hematol Oncol Clin North Am
|
2012
|
0.75
|
|
124
|
A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges.
|
Fam Cancer
|
2011
|
0.75
|
|
125
|
Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN.
|
Oncology
|
2016
|
0.75
|
|
126
|
Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.
|
Breast J
|
2015
|
0.75
|
|
127
|
Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer.
|
Obstet Gynecol
|
2016
|
0.75
|
|
128
|
Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.
|
Int J Gynecol Cancer
|
2017
|
0.75
|
|
129
|
Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer.
|
Int J Gynecol Cancer
|
2017
|
0.75
|
|
130
|
Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis.
|
Int J Gynecol Cancer
|
2016
|
0.75
|
|
131
|
Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma.
|
Int J Gynecol Cancer
|
2017
|
0.75
|
|
132
|
Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review.
|
Int J Gynecol Cancer
|
2016
|
0.75
|
|
133
|
Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.
|
Obstet Gynecol
|
2017
|
0.75
|